Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Natus Medical Inc (NASDAQ:BABY) by 227.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,795 shares of the medical equipment provider’s stock after purchasing an additional 13,060 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Natus Medical were worth $640,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Pearl River Capital LLC acquired a new position in shares of Natus Medical during the 4th quarter worth approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Natus Medical by 51.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,495 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 845 shares during the last quarter. Factorial Partners LLC acquired a new position in shares of Natus Medical during the 3rd quarter worth approximately $111,000. Paloma Partners Management Co acquired a new position in shares of Natus Medical during the 3rd quarter worth approximately $218,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Natus Medical during the 3rd quarter worth approximately $240,000. 98.37% of the stock is currently owned by hedge funds and other institutional investors.
Get Natus Medical alerts:
Several research analysts have recently commented on BABY shares. ValuEngine downgraded Natus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. BidaskClub upgraded Natus Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 21st. Zacks Investment Research downgraded Natus Medical from a “hold” rating to a “strong sell” rating in a research note on Friday, February 15th. Finally, William Blair reiterated a “market perform” rating on shares of Natus Medical in a research note on Saturday, January 12th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $36.00.
In other news, Director Robert A. Gunst sold 8,304 shares of Natus Medical stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $28.09, for a total transaction of $233,259.36. Following the completion of the transaction, the director now directly owns 32,392 shares in the company, valued at approximately $909,891.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 6,304 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $27.96, for a total value of $176,259.84. Following the completion of the sale, the director now owns 32,392 shares of the company’s stock, valued at $905,680.32. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.
Shares of NASDAQ BABY opened at $26.99 on Thursday. The company has a quick ratio of 1.54, a current ratio of 2.14 and a debt-to-equity ratio of 0.17. Natus Medical Inc has a 12 month low of $25.06 and a 12 month high of $37.95. The company has a market cap of $912.66 million, a PE ratio of 19.03 and a beta of 0.54.
Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, February 13th. The medical equipment provider reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by ($0.07). Natus Medical had a positive return on equity of 11.64% and a negative net margin of 4.32%. The business had revenue of $141.00 million for the quarter, compared to the consensus estimate of $135.80 million. During the same quarter in the prior year, the firm posted $0.42 earnings per share. The business’s revenue was up 7.3% compared to the same quarter last year. On average, research analysts expect that Natus Medical Inc will post 1.25 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Natus Medical Inc (BABY) Holdings Lifted by Los Angeles Capital Management & Equity Research Inc.” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at www.tickerreport.com/banking-finance/4219997/natus-medical-inc-baby-holdings-lifted-by-los-angeles-capital-management-equity-research-inc.html.
Natus Medical Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Read More: Do stock splits help investors?
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).
